



Virginia Commonwealth University
VCU Scholars Compass

Pediatrics Publications

Dept. of Pediatrics

2008

Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome

Mark R. Schleiss

Center for Infectious Diseases and Microbiology Translational Research

Alistair McGregor

Center for Infectious Diseases and Microbiology Translational Research

K Yeon Choi

University of Minnesota

See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/pediatrics_pubs

© 2008 Schleiss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from

http://scholarscompass.vcu.edu/pediatrics_pubs/12

This Article is brought to you for free and open access by the Dept. of Pediatrics at VCU Scholars Compass. It has been accepted for inclusion in Pediatrics Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Authors

Mark R. Schleiss, Alistair McGregor, K Yeon Choi, Shailesh V. Date, Xiaohong Cui, and Michael McVoy

Short report

Open Access

Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome

Mark R Schleiss*¹, Alistair McGregor¹, K Yeon Choi¹, Shailesh V Date², Xiaohong Cui³ and Michael A McVoy³

Address: ¹Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, 2001 6th Street SE, Minneapolis, MN 55455, USA, ²Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA and ³Division of Infectious Diseases, Department of Pediatrics, Virginia Commonwealth University School of Medicine, P.O. Box 163, MCV Station, Richmond, VA 23298, USA

Email: Mark R Schleiss* - schleiss@umn.edu; Alistair McGregor - mcre077@umn.edu; K Yeon Choi - choix207@umn.edu; Shailesh V Date - date.shailesh@gene.com; Xiaohong Cui - xcui@vcu.edu; Michael A McVoy - mmcvoy@vcu.edu

* Corresponding author

Published: 12 November 2008

Received: 15 October 2008

Virology Journal 2008, 5:139 doi:10.1186/1743-422X-5-139

Accepted: 12 November 2008

This article is available from: <http://www.virologyj.com/content/5/1/139>

© 2008 Schleiss et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In this report we describe the genomic sequence of guinea pig cytomegalovirus (GPCMV) assembled from a tissue culture-derived bacterial artificial chromosome clone, plasmid clones of viral restriction fragments, and direct PCR sequencing of viral DNA. The GPCMV genome is 232,678 bp, excluding the terminal repeats, and has a GC content of 55%. A total of 105 open reading frames (ORFs) of > 100 amino acids with sequence and/or positional homology to other CMV ORFs were annotated. Positional and sequence homologs of human cytomegalovirus open reading frames *UL23* through *UL122* were identified. Homology with other cytomegaloviruses was most prominent in the central ~60% of the genome, with divergence of sequence and lack of conserved homologs at the respective genomic termini. Of interest, the GPCMV genome was found in many cases to bear stronger phylogenetic similarity to primate CMVs than to rodent CMVs. The sequence of GPCMV should facilitate vaccine and pathogenesis studies in this model of congenital CMV infection.

Findings

Guinea pig cytomegalovirus (GPCMV) serves as a useful model of congenital infection, due to the ability of the virus to cross the placenta and infect the fetus *in utero* [1-3]. This model is well-suited to vaccine studies for prevention of congenital cytomegalovirus (CMV) infection, a major public health problem and a high-priority area for new vaccine development [4]. However, an impediment to studies in this model has been the lack of detailed DNA sequence data. Although a number of reports have identified specific gene products or clusters of genes [5-11], to date a full genomic sequence has not been available.

We recently reported the construction and preliminary sequence map of a GPCMV bacterial artificial chromosome (BAC) clone maintained in *E. coli* [12,13], and this clone was used as an initial template for sequence analysis of the full GPCMV genome. BAC DNA was purified using Clontech's NucleoBond® Plasmid Kits as described previously [14] and both strands were sequenced using an ABI PRISM® 377 DNA Sequencer, with primers synthesized, as needed, to 'primer-walk' the nucleotide sequence. In parallel, *Hind* III- and *Eco*R I-digested fragments were gel-purified and cloned into pUC and pBR322-based vectors as previously described [15]. Plasmid sequences were

determined from overlapping *Hind* III and *Eco*R I fragments using the map coordinates originally described by Gao and Isom [16]. These sequences were compared to the BAC sequence to facilitate assembly of a full-length contiguous sequence. Since the cloning of the BAC in *E. coli* involved insertion of BAC origin sequences into the *Hind* III "N" region of the viral genome, sequence obtained from this specific restriction fragment cloned in pBR322 was utilized for assembly of the final contiguous sequence; analysis of this sequence confirmed that there were no adventitious deletions in the *Hind* III "N" region generated during the original BAC cloning process. Since a deletion in the *Hind* III "D" region occurred during cloning of the GPCMV BAC in *E. coli* [17], DNA sequence from a plasmid containing the full-length *Hind* III "D" fragment was similarly obtained, and used for assembly of the final contiguous sequence. The GPCMV genomic sequence has been deposited with GenBank (Accession Number [FJ355434](#)).

Sequence analysis of GPCMV revealed a genome length of 232,678 bp with a GC content of 55%. This value is in agreement with the value of 54.1% determined previously by CsCl buoyant density centrifugation [18]. A total of 326 open reading frames (ORFs) were identified that were capable of encoding proteins of ≥ 100 amino acids (aa). For ORFs predicted by the sequence analysis that had substantial overlap with other adjacent or complementary GPCMV ORFs that appeared to encode gene products that were highly conserved in other cytomegaloviruses, only those sequences with $< 60\%$ overlap with these highly conserved ORFs were further analyzed. ORFs homologous to those encoded by other CMVs with an e-value of < 0.1 and ≥ 100 aa were identified, based on comparisons analyzed using NCBI Blast (blastall version 2.2.16). Of the ORFs so identified, 104 had sequence and/or positional homology to one or more ORFs encoded by human (HCMV), murine (MCMV), rat (RCMV), rhesus (RhCMV), chimpanzee (CCMV), or tupaia herpesvirus (THV) cytomegaloviruses (Table 1). Of note, homologs of HCMV ORFs *UL23* through *UL122* were identified [19]. For ease of nomenclature, we have designated these ORFs using upper case font (*GP23* through *GP122*). ORFs with homologs in other CMVs that do not correspond to HCMV *UL23* through *UL122* have been designated with a lower case "gp" prefix. Homologs of HCMV *UL41a* (69 aa; *gp38.2*), *UL51* (99 aa; *GP51*), and *UL91* (87 aa; *GP91*) were annotated in these initial analyses, based primarily on positional, and not sequence, homology to the respective HCMV ORFs. Three ORFs, homologs of MHC class I genes known to be encoded by multiple other CMVs (*gp147-149*, Table 1) were also identified. One ORF, *gp1* (homolog of CC chemokines), did not have a positional or sequence homolog when compared to other CMVs, but was included in the annotation because of its previous

molecular characterization [9]. Including ORFs with mapped exons, the total number of ORFs annotated in this preliminary analysis was 105 [Table 1].

A map of the GPCMV genome illustrating the relative positions of these ORFs is shown in Fig. 1. ORFs that represent homologs of the individual exons of spliced HCMV genes, in particular *UL89* (terminase) and *UL112/UL113* (replication accessory protein) are annotated separately. The splice junction for the *GP89* mRNA was predicted based on comparisons to other CMVs. For the *UL112/113* region, further studies will be required to map the precise splicing patterns of the putative transcripts encoded by this region of the GPCMV genome. Similarly, the ORF encoding the sequence homolog of the HCMV IE transactivator, *UL122*, has been annotated without regard to the splicing events previously shown to take place in this region of the genome [20]; further analyses of cDNA from this and other GPCMV genome regions of IE transcription, including those encoded in the *Hind* III 'D' region of the genome, will likely result in annotation of multiple heretofore unidentified ORFs. A comprehensive table of all ORFs > 25 aa and their homology to other CMV genomes is provided in additional files 1 and 2. As RNA analyses are completed, the total number of annotated GPCMV ORFs will expand in number.

The schematic representation of GPCMV ORFs demonstrated in Fig. 1 highlights several gene families of particular interest. Of particular interest and importance to vaccine studies in the guinea pig model are conserved homologs of the ORFs encoding major envelope glycoproteins *gB*, *gH/gL/gO*, and *gM/gN*. These glycoproteins are important determinants of humoral immune responses in the setting of CMV infection, and serve as potential subunit vaccine candidates. Of these, the *gB* homolog has been demonstrated to confer protection against congenital GPCMV infection in subunit vaccine studies [21-23]. Homologs of putative HCMV immune modulation genes, including G-protein coupled receptors and major histocompatibility class I homologs, were also identified [24]. Also of interest was the presence of multiple *US22* gene family homologs, heavily clustered near the rightward terminus of the GPCMV genome. These ORFs predict protein products that are analogous to the MCMV dsRNA-binding proteins, *M142* and *M143*, that have been shown to inhibit dsRNA-activated antiviral pathways [25,26]. Members of this family have also been implicated in macrophage tropism in MCMV [27]. Our sequence analysis also confirmed the findings of Liu and Biegalka [8] that the GPCMV genome does not encode a positional homolog of the antiapoptotic HCMV *UL36* gene [28]. However, an ORF with homology to *R36*, which encodes the presumed RCMV cell death suppressor, was identified (*gp29.1*, Table 1). Further studies will be

Table 1: GPCMV Open Reading Frames (ORFs)

ORF	Strand	Position		Size (aa)	Protein Characteristics and Cytomegalovirus Homologs
		From	To		
gp1	C	12701	13006	101	GPCMV MIP I-alpha; homology to multiple CC chemokines
gp2		15098	15949	283	Homology to MCMV M69 ^a
gp3	C	17461	19827	788	Homology to THV T5 ^b ; US22 superfamily
gp4	C	21093	21416	107	Homology to RCMV r136 ^d
gp5	C	26985	28097	370	Homology to MCMV m32 ^a
gp6		30089	30454	121	Homology to MCMV glycoprotein family m02 ^a
gp7	C	32003	32308	101	Homology to RhCMV rh42 ^c
GP23	C	33561	34763	400	UL23 homolog; US22 gene superfamily
GP24	C	35000	36217	405	UL24 homolog; US22 superfamily
gp24.1		36802	37224	140	Homology to MCMV M34 protein ^a
GP25		37187	38455	422	UL25 homolog; tegument protein
GP26	C	38621	39058	145	UL26 homolog
GP27	C	39508	41472	654	UL27 homolog
GP28	C	41572	42639	355	UL28 homolog; US22 superfamily
GP28.1	C	43344	44546	400	UL28 homolog; US22 superfamily
GP28.2	C	44912	46099	395	UL28 homolog; US22 superfamily
GP29	C	46211	46882	223	UL29 homolog; US22 superfamily
gp29.1	C	47579	48034	151	Homology to RCMV R36 protein ^d ; potential homolog of viral cell death suppressor
GP30	C	49363	51060	565	UL30 homolog
GP31		51354	52832	492	UL31 homolog
GP32	C	53073	54626	518	UL32 homolog
GP33		54846	56129	427	UL33 homolog; 7-TMR GPCR superfamily
GP34		56482	58065	527	UL34 homolog
GP35		58269	59927	552	UL35 homolog
GP37	C	60047	60964	305	UL37 homolog
GP38	C	61321	62385	354	UL38 homolog
gp38.1	C	62960	63817	436	Positional homolog of HCMV UL40

Table 1: GPCMV Open Reading Frames (ORFs) (Continued)

gp38.2	C	63876	65186	69	Positional homolog of HCMV UL41a
gp38.3	C	65881	66735	284	Positional homolog of HCMV UL42
gp38.4	C	67254	67619	121	Homology to RCMV r42 ^d
GP43	C	68208	69221	337	UL43 homolog
GP44	C	69209	70432	407	UL44 homolog
GP45	C	71144	73933	929	UL45 homolog
GP46	C	74036	74833	265	UL46 homolog
GP47		75441	77846	801	UL47 homolog
GP48		78051	84332	2093	UL48 homolog
GP49	C	84746	86386	546	UL49 homolog
GP50	C	86362	87426	354	UL50 homolog
GP51	C	87551	87850	99	UL51 homolog; terminase subunit
GP52		88170	89750	526	UL52 homolog
GP53		89743	90729	328	UL53 homolog
GP54	C	90821	94174	1117	UL54 homolog; DNA polymerase
GP55	C	94216	96921	901	UL55 homolog; glycoprotein B
GP56	C	96818	99085	755	UL56 homolog; terminase subunit
GP57	C	99236	102919	1227	UL57 homolog
gp57.1	C	104872	105258	128	Homology to RCMV r23.1 ^d
gp57.2		107338	107712	124	Homology to RCMV R53 ^d
GP69	C	108547	111678	1043	UL69 homolog
GP70	C	112387	115590	1067	UL70 homolog; helicase-primase
GP71		115589	116365	258	UL71 homolog
GP72	C	116528	117601	357	UL72 homolog; dUTPase
GP73		117683	118084	133	UL73 homolog; glycoprotein N
GP74	C	118031	119143	370	UL74 homolog; glycoprotein O
GP75	C	119595	121766	723	UL75 homolog; glycoprotein H
GP76		121931	122770	279	UL76 homolog
GP77		122484	124343	619	UL77 homolog

Table 1: GPCMV Open Reading Frames (ORFs) (Continued)

GP78		124725	125969	414	UL78 homolog; 7-TMR GPCR superfamily
GP79	C	126164	127111	315	UL79 homolog
GP80		126972	129281	769	UL80 homolog; CMV protease
GP82	C	129576	131141	521	UL82 homolog; pp71
GP83	C	131361	133058	565	UL83 homolog; pp65
GP84	C	133286	134737	483	UL84 homolog
gp84.l		134994	135476	160	Homolog of RhCMV rh116 ^e
GP85	C	135035	135946	303	UL85 homolog
GP86	C	136227	140276	1349	UL86 homolog
GP87		140657	143578	973	UL87 homolog
GP88		143481	144752	423	UL88 homolog
GP89ex2	C	144798	145928	376	UL89 homolog; terminase subunit, exon 2
GP91		146356	146619	87	UL91 homolog
GP92		146616	147245	209	UL92 homolog
GP93		147456	148985	509	UL93 homolog
GP94		149118	149873	251	UL94 homolog
GP89ex1	C	150285	151166	291	UL89 homolog; terminase subunit, exon 1
GP95		151284	152489	401	UL95 homolog
GP96		152722	153084	120	UL96 homolog
GP97		153164	154981	605	UL97 homolog; protein kinase
GP98		155001	156788	595	UL98 homolog; alkaline nuclease
GP99		156701	157222	173	UL99 homolog; pp28
gp99.l		157406	158020	204	Homology to RCMV r4 ^d
GPI100	C	157529	158578	349	UL100 homolog; glycoprotein M
GPI102		158908	161193	761	UL102 homolog
GPI103	C	161307	162104	265	UL103 homolog
GPI104	C	162067	164160	697	UL104 homolog; portal
GPI105		164000	166783	927	UL105 homolog; helicase-primase
gp105.l		176502	176894	130	Homology to RhCMV rh55 ^c

Table 1: GPCMV Open Reading Frames (ORFs) (Continued)

GPI12ex1		177066	177839	258	ULI12 homolog; replication accessory protein, exon 1
GPI12ex2		178403	179257	284	ULI12/ULI13 homolog; replication accessory protein, exon 2
GPI14	C	179168	180259	363	ULI14 homolog; uracil glycosylase
GPI15	C	180325	181101	258	ULI15 homolog; glycoprotein L
GPI16	C	181146	181994	282	Homology to THV tI16 ^b ; possible functional homolog of ULI19; Fc receptor/immunoglobulin binding domains
GPI17	C	182202	182777	191	ULI17 homolog
GPI19.1	C	185103	185591	162	ULI19 homolog; homology to MCMV MI19.1 ^a
GPI21	C	186635	187681	348	ULI21 homolog; homology to THV tI21.4 ^b
GPI22	C	188292	189260	322	ULI22 homolog; HCMV IE2; immediate early transactivator
gp123		195838	196893	351	MCMV IE2 homolog ^a ; US22 superfamily
gp138	C	201275	202750	491	Homology to RCMV rI38 ^d
gp139	C	204624	206717	697	Homology to THV T5 ^b ; US22 superfamily
gp140		206446	206853	135	Homology to CCMV ULI32 ^e
gp141	C	206977	208584	535	Homology to HCMV US23 ^h ; US22 superfamily
gp142	C	208852	210546	564	Homology to HCMV US24 ^h ; US22 superfamily
gp143	C	210799	212532	577	Homology to THV T5 ^b ; US22 superfamily
gp144	C	213034	215328	764	Homology to US26 ^h ; US22 gene superfamily
gp145	C	215601	217499	632	Homology to HCMV IRS1/TRS1 ^h ; US22 superfamily
gp146	C	218106	219839	577	Homology to HCMV IRS1/TRS1 ^h ; US22 superfamily
gp147	C	223464	225026	520	MHC class I homolog
gp148	C	225938	227389	483	MHC class I homolog
gp149	C	228845	230728	627	MHC class I homolog

^a Genbank [NC_004065.1](#)^b Genbank [NC_004065.1](#)^c Genbank [NC_006150.1](#)^d Genbank [AF232689.2](#)^e Genbank [YP_068209.1](#)^f Genbank [AY486477.1](#)^g Genbank [NC_003521.1](#)^h Genbank [NC_001347](#)




Figure 1
Protein Coding Map of GPCMV Genome. Schematic representation of the GPCMV genome demonstrating ORFs described in the text. GPCMV ORFs with positional and/or sequence homology to HCMV ORFs are indicated in bold with upper case prefixes (*GP23* through *GP122*). ORFs that lack sequence or positional homologs in HCMV but share homology with ORFs in other CMVs are indicated with lower case prefixes (see Table 1). Only the 5' terminal repeat (TR) is shown; however, in about 50% of genomes the TR is duplicated at the 3' end [18]. Color-coding indicates ORFs of interest for vaccine and pathogenesis studies: blue, envelope glycoprotein homologs; green, putative immune evasion/immune modulation gene homologs; red, *US22* superfamily homologs.




Figure 2
Comparison of GPCMV Glycoproteins with CMV Homologs. Sequences of GPCMV glycoproteins were aligned with glycoproteins from six other CMV genomes (HCMV, MCMV, RCMV, RhCMV, THV, and CCMV) using both ClustalW [37] and Muscle [38] using default parameters. Phylogenetic trees (neighbor joining) were generated from these alignments using Jalview. Numbers at each node indicate mismatch percentages. Interestingly, GPCMV sequences closely match THV sequences (see also, supplementary information), and generally appear closer to primate CMV glycoproteins in pair-wise comparisons than to rodent CMV glycoproteins, as previously observed for gB [39]. Clustal comparisons for conserved glycoproteins gB (GP55; Panel A) and gN (GP73; Panel B) are indicated.

required to determine whether this putative gene supplies a UL36-like function.

It was also of interest to note the presence of ORFs that have apparent homology to the MCMV *M129-133* region. This region has positional homologs in human and primate CMVs [29-31], but is absent in THV [32]. Recently, it was determined that passage of GPCMV in cultured fibroblasts promotes the deletion of a ~1.6-kb locus containing potential positional homologs of this gene cluster. The presence of this 1.6 kb locus was found by Inoue and colleagues to be associated with an enhanced pathogenesis of GPCMV *in vivo* [33]. We independently confirmed the presence of this locus and its sequence in our salivary gland-derived viral stocks, and have included this sequence in our GenBank annotation (Accession Number [FJ355434](#)). Further studies will be required to fully annotate the transcripts encoded by this region of the GPCMV genome. Interestingly, the original GPCMV BAC clone that we sequenced was derived using GPCMV viral DNA obtained after long-term tissue culture passage of ATCC 2122 viral stock, and not surprisingly this BAC was found to lack the 1.6 kb virulence locus [12]. Subsequently, PCR and preliminary sequencing of a more recently obtained GPCMV BAC clone with an excisable origin of replication [17] revealed that the 1.6-kb sequence was retained in this clone. The apparent modifications of this locus that occur following viral passage on fibroblast cells are reminiscent of the mutations and deletions that occurred during fibroblast-passage of HCMV [34] and rhesus CMV [35]. The congruence of these events suggests that the selective pressures that promote mutational inactivation of genes in this region may be similar across viral species. Additional analyses, including sequencing of a full-length GPCMV genome derived from replicating virus *in vivo*, will be required to determine what other deletions or mutations are present in genomes from tissue culture-passaged viruses. Since additional ORFs are likely to be identified by these analyses, we have annotated the first ORF identified in the BAC sequence to the right of this 1.6 kb region as *gp138* (Fig. 1), to allow for ease of nomenclature as ORFs in this virulence locus are better characterized. Application of other genome sequence analysis methods, including identification of small or overlapping genes and further assessment of mRNA splicing or unconventional translation signals, will likely result in identification of other putative ORFs in future studies [36].

Comparisons of GPCMV ORFs with sequences from other CMV genomes yielded interesting results. ORF translations were compared with all proteins from the 6 sequenced CMV genomes (HCMV, MCMV, RCMV, RhCMV, THV, and CCMV), and hits with *e*-values less than $1e^{-5}$ were aligned individually for each protein, using both ClustalW (version 1.82; [37]) and Muscle (version

3.6; [38]). The alignments were then used to generate trees based on neighbor-joining using JalView. Clustal trees for glycoproteins B (*GP55*) and N (*GP73*) are shown in Fig. 2, with distance scores indicated. Overall, comparison of the various glycoproteins (gB, gM, gH, and gO) yielded similar phylogenies, with GPCMV glycoproteins generally appearing closer to primate CMVs than rodent CMVs [39], except for the gN homolog, which appears closer to rodents. ClustalW and Muscle comparisons of GPCMV ORFs with homologous ORFs from the other sequenced CMVs are provided in additional file 3.

In summary, the complete DNA sequence of GPCMV was determined, using a combination of sequencing of BAC DNA, viral DNA, and cloned *Hind* III and *Eco*RI fragments. These analyses identified both conserved ORFs found in all mammalian CMVs, as well as the presence of novel genes apparently unique to the GPCMV. These similarities underscore the usefulness of the guinea pig model, with positive translational implications for development and testing of CMV intervention strategies in humans. Further characterization of the GPCMV genome should facilitate ongoing vaccine and pathogenesis studies in this uniquely useful small animal model of congenital CMV infection.

Competing interests

The authors declare that they have no competing interest. SVD is an employee of Genentech Corporation.

Authors' contributions

MRS cloned viral fragments, performed sequence analysis, analyzed the data and prepared the communication. AM and XC cloned the GPCMV BACs. AM cloned individual genes for sequence analysis. AM, XC and KYC, performed sequence analysis, participated in data analysis, and helped in preparation of the communication. MAM cloned viral DNA fragments, performed sequence analysis, participated in BAC cloning, and aided in preparation of the communication. SVD performed comparative genomic analyses and comparisons and aided in the preparation of the communication.

Additional material

Additional file 1

ORFs of ≥ 25 aa (tab A), 50 aa (tab B), or 100 aa (tab C) with Blast analysis against other sequenced CMV genomes; *e*-value cutoff of 0.1. Click here for file

[<http://www.biomedcentral.com/content/supplementary/1743-422X-5-139-S1.xls>]

Additional file 2

ORFs of ≥ 25 aa (tab A), 50 aa (tab B), or 100 aa (tab C) with Blast analysis against other sequenced CMV genomes; e-value cutoff of $1e^{-5}$.

Click here for file

[http://www.biomedcentral.com/content/supplementary/1743-422X-5-139-S2.xls]

Additional file 3

Phylogenetic trees for glycoproteins gB, gH, gO, gL, gM and gN, IRS 1–3 family, and GP116 (functional homolog of UL119; Fc receptor/immunoglobulin binding domains). Alignments generated using both ClustalW and Muscle, as described in the text.

Click here for file

[http://www.biomedcentral.com/content/supplementary/1743-422X-5-139-S3.pdf]

Acknowledgements

Grant support was provided from NIH HD044864-01 and HD38416-01 (to MRS) and R01AI46668 (to MAM). The authors acknowledge helpful discussions and input from Becket Feierbach (Genentech, Inc.). The authors also acknowledge the technical contributions of Yonggen Song and the gift of the Hind III "D" plasmid from HC Isom, Penn State University.

References

- Kern ER: **Pivotal role of animal models in the development of new therapies for cytomegalovirus infections.** *Antiviral Res* 2006, **71**:164-71.
- Schleiss MR: **Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV).** *J Clin Virol* 2002, **25(Suppl 2)**:S37-49.
- Schleiss MR: **Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.** *J Clin Virol* 2008, **41**:224-30.
- Schleiss MR: **Cytomegalovirus vaccine development.** *Curr Top Microbiol Immunol* 2008, **325**:361-82.
- McVoy MA, Nixon DE, Adler SP: **Circularization and cleavage of guinea pig cytomegalovirus genomes.** *J Virol* 1997, **71**:4209-17.
- Fox DS, Schleiss MR: **Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog.** *Virus Genes* 1997, **15**:255-64.
- Schleiss MR, McGregor A, Jensen NJ, Erdem G, Aktan L: **Molecular characterization of the guinea pig cytomegalovirus UL83 (pp65) protein homolog.** *Virus Genes* 1999, **19**:205-221.
- Liu Y, Biegalka BJ: **Characterization of a cluster of late genes of guinea pig cytomegalovirus.** *Virus Genes* 2001, **23**:247-56.
- Haggerty SM, Schleiss MR: **A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus.** *Virus Genes* 2002, **25**:271-9.
- McGregor A, Liu F, Schleiss MR: **Identification of essential and non-essential genes of the guinea pig cytomegalovirus (GPCMV) genome via transposome mutagenesis of an infectious BAC clone.** *Virus Res* 2004, **101**:101-8.
- Paglino JC, Brady RC, Schleiss MR: **Molecular characterization of the guinea-pig cytomegalovirus glycoprotein L gene.** *Arch Virol* 1999, **144**:447-62.
- McGregor A, Schleiss MR: **Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli.** *Mol Genet Metab* 2001, **72**:15-26.
- Schleiss MR, Lacayo J: **The Guinea-Pig Model of Congenital CMV Infection.** In *Cytomegaloviruses: Molecular Biology and Immunology* Edited by: Reddehase MJ, Lemmermann N. Horizon Scientific Press; 2006:525-50.
- McGregor A, Liu F, Schleiss MR: **Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83).** *J Virol* 2004, **78**:9872-89.
- Schleiss MR: **Cloning and characterization of the guinea pig cytomegalovirus glycoprotein B gene.** *Virology* 1994, **202**:173-85.
- Gao M, Isom HC: **Characterization of the guinea pig cytomegalovirus genome by molecular cloning and physical mapping.** *J Virol* 1984, **52**:436-47.
- Cui X, McGregor A, Schleiss MR, McVoy MA: **Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication.** *J Virol Methods* 2008, **149**:231-9.
- Isom HC, Gao M, Wigdahl B: **Characterization of guinea pig cytomegalovirus DNA.** *J Virol* 1984, **49**:426-36.
- Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA 3rd, Kouzarides T, Martignetti JA, et al.: **Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.** *Curr Top Microbiol Immunol* 1990, **154**:125-69.
- Yin CY, Gao M, Isom HC: **Guinea pig cytomegalovirus immediate-early transcription.** *J Virol* 1990, **64**:1537-48.
- Bourne N, Schleiss MR, Bravo FJ, Bernstein DI: **Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection.** *J Infect Dis* 2001, **183**:59-64.
- Schleiss MR, Bourne N, Bernstein DI: **Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection.** *J Infect Dis* 2003, **188**:1868-74.
- Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI: **Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.** *J Infect Dis* 2004, **189**:1374-81.
- Powers C, DeFilippis V, Malouli D, Früh K: **Cytomegalovirus immune evasion.** *Curr Top Microbiol Immunol* 2008, **325**:333-59.
- Valchanova RS, Picard-Maureau M, Budt M, Brune WW: **Murine cytomegalovirus m142 and m143 are both required to block protein kinase R-mediated shutdown of protein synthesis.** *J Virol* 2006, **80**:10181-90.
- Child SJ, Hanson LK, Brown CE, Janzen DM, Geballe AP: **Double-stranded RNA binding by a heterodimeric complex of murine cytomegalovirus m142 and m143 proteins.** *J Virol* 2006, **80**:10173-80.
- Ménard C, Wagner M, Ruzsics Z, Holak K, Brune W, Campbell AE, Koszinowski UH: **Role of murine cytomegalovirus US22 gene family members in replication in macrophages.** *J Virol* 2003, **77**:5557-70.
- Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS: **A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation.** *Proc Natl Acad Sci USA* 2001, **98**:7829-34.
- Lagenaur LA, Manning WC, Vieira J, Martens CL, Mocarski ES: **Structure and function of the murine cytomegalovirus sgg1 gene: a determinant of viral growth in salivary gland acinar cells.** *J Virol* 1994, **68**:7717-7727.
- Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ: **Genetic content of wild-type human cytomegalovirus.** *J Gen Virol* 2004, **85**:1301-1312.
- Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC: **Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.** *J Virol* 2008, **82**:60-70.
- Bahr U, Darai G: **Analysis and characterization of the complete genome of tupaia (tree shrew) herpesvirus.** *J Virol* 2001, **75**:4854-70.
- Nozawa N, Yamamoto Y, Fukui Y, Katano H, Tsutsui Y, Sato Y, Yamada S, Inami Y, Nakamura K, Yokoi M, Kurane I, Inoue N: **Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture.** *Virology* 2008, **379**:45-54.
- Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR: **Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.** *J Virol* 1996, **70**:78-83.

35. Oxford KL, Eberhardt MK, Yang KW, Strelow L, Kelly S, Zhou SS, Barry PA: **Protein coding content of the ULb' region of wild-type rhesus cytomegalovirus.** *Virology* 2008, **373**:181-8.
36. Brocchieri L, Kledal TN, Karlin S, Mocarski ES: **Predicting coding potential from genome sequence: application to betaherpesviruses infecting rats and mice.** *J Virol* 2005, **79**:7570-96.
37. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins DG, Thompson JD: **Multiple sequence alignment with the Clustal series of programs.** *Nucleic Acids Research* 2003, **31**:3497-3500.
38. Edgar RC: **MUSCLE: multiple sequence alignment with high accuracy and high throughput.** *Nucleic Acids Research* 2004, **32**:1792-1797.
39. Beuken E, Slobbe R, Bruggeman CA, Vink C: **Cloning and sequence analysis of the genes encoding DNA polymerase, glycoprotein B, ICPI8.5 and major DNA-binding protein of rat cytomegalovirus.** *J Gen Virol* 1996, **77**:1559-62.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

